IL-12 Inhibitors are a class of pharmaceuticals designed to target and inhibit the activity of interleukin-12 (IL-12); a cytokine involved in the immune response. By blocking IL-12, these inhibitors aim to modulate the immune system and reduce inflammation. IL-12 Inhibitors find application in the treatment of various inflammatory and autoimmune diseases, including psoriasis, rheumatoid arthritis, Crohn's disease, and multiple sclerosis, among others. According to the World Health Organization (WHO), psoriasis affects approximately 2-3% of the global population, with higher prevalence rates reported in Europe and North America. In Europe, an estimated 1.5% of the population is affected by rheumatoid arthritis, and it is a leading cause of disability. Crohn's disease, a chronic inflammatory bowel disease, affects approximately 1.5 million people in Europe and 1-1.3 million people in the United States. Multiple sclerosis is estimated to affect around 700,000 people in Europe and 1 million people in the United States, as per the respective countries' health authorities.
The growth of the IL-12 Inhibitor market is driven by several factors. These include the increasing understanding of the role of IL-12 in inflammatory and autoimmune diseases, a growing patient population, advancements in research and development, and the introduction of novel IL-12 inhibitors drugs with improved efficacy and safety profiles. Companies such as AbbVie, Madrigal Pharma, VBL Therap, AI Therap, Akesobio, Ventyx Biosci, Amgen, Alvotech, Samsung, Pfizer, Antisoma, ESSA Pharma, Fuji Pharma, Cipla, Teva cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, VBL Therapy is currently conducting a clinical trial of the drug VB-201 for the treatment of psoriasis.
Key Developments:
- In Sep 2022, AI Therapeutics in collaboration with Yale University completed a phase II trial of Apilimod dimesylate in COVID-2019 infections in the USA.
- In July 2022, Akeso completed the phase III trial of Ebdarokimab in Plaque psoriasis.
Approved IL-12 Inhibitor molecules
- Ozespa (briakinumab)
IL-12 Inhibitor Pipeline Molecules
- Apilimod (STA-5326)
- VB-201
- Apilimod dimesylate (AIT-101)
- Ebdarokimab (AK101)
- VTX958
- ABP 654 (ustekinumab biosimilar)
- AVT04 (ustekinumab biosimilar)
- BAT2206 (ustekinumab biosimilar)
- CT-P43 (ustekinumab biosimilar)
- SB17 (ustekinumab biosimilar)
- AN2898
- AS1409
- BFI-751 (ustekinumab biosimilar)
- Bmab1200 (ustekinumab biosimilar)
- DMB-3115 (ustekinumab biosimilar)
- FYB202 (ustekinumab biosimilar)
- NeuLara (ustekinumab biosimilar)
- RT-111 (ustekinumab biosimilar)
- Hypochlorous acid (PR022)
Clinical Activity and Development of IL-12 Inhibitor
In the IL-12 Inhibitor space, more than 10 companies are conducting more than 50 clinical trials in this category of drugs. For instance,
- In April 2023, AI Therapeutics released pharmacodynamics data from a phase IIa trial of Apilimod dimesylate in Amyotrophic Lateral Sclerosis.
- In Oct 2022, VBL Therapeutics completed a phase II trial of VB-201 for COVID-2019 infections in Israel.
|
Product Name |
Total Studies |
|
Apilimod (STA-5326) |
7 |
|
VB-201 |
6 |
|
Apilimod dimesylate (AIT-101) |
4 |
|
Ebdarokimab (AK101) |
4 |
|
VTX958 |
3 |
|
ABP 654 (ustekinumab biosimilar) |
2 |
|
AVT04 (ustekinumab biosimilar) |
2 |
|
BAT2206 (ustekinumab biosimilar) |
2 |
|
CT-P43 (ustekinumab biosimilar) |
2 |
|
JNJ-26483327 |
1 |
Target Indication Analysis of IL-12 Inhibitor
IL-12 Inhibitors are targeted therapies that specifically inhibit the activity of interleukin-12 (IL-12), a cytokine involved in the immune response. By blocking IL-12, these inhibitors aim to treat a range of inflammatory and autoimmune diseases, including psoriasis, rheumatoid arthritis, Crohn's disease, and multiple sclerosis. IL-12 plays a crucial role in promoting inflammation and immune responses, and its excessive activity is implicated in the pathogenesis of these conditions. IL-12 Inhibitors, by modulating the immune system and reducing inflammation, aim to alleviate symptoms, slow disease progression, and improve the quality of life for patients suffering from these target indications.
IL-12 Inhibitor Market Regional Analysis
IL-12 Inhibitor Market
The global IL-12 Inhibitor market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall US regional market analysis of IL-12 Inhibitors indicates a promising outlook for this class of pharmaceuticals. The market is driven by a high prevalence of inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, and Crohn's disease. The increasing aging population and rising awareness of these conditions further contribute to market growth. Additionally, advancements in biotechnology and targeted therapies have led to the development of more effective IL-12 Inhibitors, offering improved treatment options. The growth of the IL-12 Inhibitor market is primarily driven by several key factors. Firstly, the increasing understanding of the role of IL-12 in inflammatory and autoimmune diseases has heightened the demand for targeted therapies. IL-12 Inhibitors offer a specific and effective treatment option by modulating the immune response and reducing inflammation. Secondly, the growing patient population suffering from these diseases, coupled with the need for long-term management, drives the demand for IL-12 Inhibitors. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for IL-12s. These countries are increasingly adopting IL-12s due to their efficacy and potential to improve patient outcomes. On the other hand, the IL-12 Inhibitor market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the IL-12 Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
IL-12 Inhibitor drugs are used in the management of a range of inflammatory and autoimmune diseases, including psoriasis, rheumatoid arthritis, Crohn's disease, and multiple sclerosis.
The growth of the IL-12 Inhibitor market is primarily driven by several key factors. Firstly, the increasing understanding of the role of IL-12 in inflammatory and autoimmune diseases has heightened the demand for targeted therapies. IL-12 Inhibitors offer a specific and effective treatment option by modulating the immune response and reducing inflammation. Secondly, the growing patient population suffering from these diseases, coupled with the need for long-term management, drives the demand for IL-12 Inhibitors.
The major players in this space are AbbVie, Madrigal Pharma, VBL Therap, AI Therap, Akesobio, Ventyx Biosci, Amgen, Alvotech, Samsung, Pfizer, Antisoma, ESSA Pharma, Fuji Pharma, Cipla, Teva. a.
The market for IL-12 Inhibitors faces restraints due to potential side effects associated with long-term usage, such as increased risk of infections and autoimmune reactions. Additionally, the high cost of IL-12 Inhibitors and limited reimbursement coverage may hinder their widespread adoption and accessibility in the market.
- Madrigal Pharma
- Samsung
- Pfizer
- Antisoma
- VBL Therap
- AI Therap
- Akesobio
- ESSA Pharma
- Fuji Pharma
- Cipla
- Teva
- Ventyx Biosci
- Amgen
- Alvotech